Navigation Links
PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
Date:9/8/2008

actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. PAREXEL Closes the Acquisition of ClinPhone
4. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
5. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
6. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
8. PAREXEL Expands Global Clinical Logistics Capabilities
9. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
10. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
11. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... folks, this is my last article of the year, and I ... so my New Year's resolution for this column is bring back ... problem is that I simply have not gone to as many ... I will need to remedy!) , ,Looking over 2006, my focus ...
... on Google , Yahoo , or MSN ... Today, even the experts aren't sure exactly what it's going ... pay-per click (PPC) infrastructures to increase the relevancy and quality ... link farms and other sites without original or meaningful content. ...
... Wis. - The nation's space agency announced this month it ... enough to pack for the longer trip to Mars . ... bypass the Earth's lifeless satellite and head directly for ... others say the government should get out of the business of ...
Cached Biology Technology:2006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5It takes more than money to reach the top 2It takes more than money to reach the top 3It takes more than money to reach the top 4Flying to the moon? Take Wisconsin tech along 2Flying to the moon? Take Wisconsin tech along 3Flying to the moon? Take Wisconsin tech along 4
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... that restoring a gene often silenced in lung cancer causes ... new strategy for treating the disease. , The research ... or silenced in a large majority of lung cancers, and ... pancreas. The work was led by scientists at The Ohio ...
... Researchers at the Salk Institute for Biological Studies discovered ... strands of DNA to protect the integrity of chromosomes. ... question that has long puzzled scientists. , The natural ... DNA that a cell's repair machinery is designed to ...
... have discovered the presence of functional ion channels in ... like electrical wires and permit ESCs, versatile cells that ... of the body, to conduct and pass along electric ... these channels in implanted cells, derived from stem cells, ...
Cached Biology News:Restoring silenced suppressor gene kills lung-cancer cells 2Normal chromosome ends elicit a limited DNA damage response 2Stem cells' electric abilities might help their safe clinical use 2
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Mitochondria Derived Activator of Caspase/DIABLO Liquid. ... 7.5 AVOID FREEZE/THAW CYCLES. Amino acid residues 56 ... terminal His•Tag ® sequence was expressed in ... is released along with cytochrome c ...
... Decorin ( Abpromise for all ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to ... of Human Decorin (fragment 36-49 of ... Entrez GeneID: ...
Biology Products: